Comparing the current results to its competitors, Cg Oncology Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Cg Oncology Inc 's competitors' average revenue growth of 149.26 %, achieved in the same quarter.
December 5, 2024
: In recent developments within oncological therapies, particularly in the treatment of non-muscle invasive bladder cancer (NMIBC), Cretostimogene Grenadenorepvec, an innovative oncolytic immunotherapy, marks a significant milestone. This article critically examines the data supporting its efficacy in delivering sustained and durable complete responses in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC patients, juxtaposed with its market performance over the month.Bladder cancer remains a challenging issue, with NMIBC comprising a substantial percentage of cases. The standard treatment involves BCG therapy; however, a subset of patients remains unresponsive. Recent therapeutic solutions have so...
June 6, 2024
In a recent publication in the prestigious Nature Medicine journal, CG Oncology has announced the final results from its CORE-001 study involving the use of Cretostimogene Grenadenorepvec (CG0070) in combination with Pembrolizumab as a potential treatment for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). This groundbreaking study sheds light on a potential new immunotherapy combination that could revolutionize the field of bladder cancer treatment.Facts from the CORE-001 Study:1. Cretostimogene Grenadenorepvec (CG0070): CG0070 is a virus-based immunotherapy developed by CG Oncology. It is designed to selectively replicate in cancer cells and trigger an immune respon...
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address significant unmet medical needs. Their business model revolves around identifying and advancing potential drug candidates that target specific diseases or conditions, conducting extensive research and development to ensure safety and efficacy, and ultimately seeking regulatory approvals and entering the market to make these therapies accessible to patients worldwide. Protara leverages collaborations and partnerships within the healthcare industry to support their research efforts and drive business growth.
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.
Sources:
Cg Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cg Oncology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
